Chemical Nameavalglucosidase alfa-ngp
Dosage FormInjection (intravenous; 100 mg)
Drug ClassEnzymes
CompanySanofi Genzyme
Approval Year2021


  • For the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nexviazyme (avalglucosidase alfa-ngp) Prescribing Information2021Genzyme Corporation Cambridge, MA